150 related articles for article (PubMed ID: 33435822)
1. Evaluating the incidence of engraftment syndrome with different melphalan formulations in adult multiple myeloma and immunoglobulin light chain amyloidosis patients undergoing autologous hematopoietic cell transplantation.
Kowalski KE; Wheeler SE; Adams CB; Voils SA; Richards AI
J Oncol Pharm Pract; 2022 Mar; 28(2):274-281. PubMed ID: 33435822
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the adverse effects of melphalan formulations.
Xiang E; Ni J; Glotzbecker B; Laubach J; Soiffer R; McDonnell AM
J Oncol Pharm Pract; 2019 Oct; 25(7):1631-1637. PubMed ID: 30336728
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation.
Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Wolf RC; Kumar SK; Gertz MA
Bone Marrow Transplant; 2019 Jul; 54(7):1077-1081. PubMed ID: 30390060
[TBL] [Abstract][Full Text] [Related]
4. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study.
Sarosiek S; Lee MH; Doros G; Edwards CV; Quillen K; Brauneis D; Shelton AC; Sanchorawala V; Sloan JM
Transplant Cell Ther; 2023 Nov; 29(11):695.e1-695.e7. PubMed ID: 37607644
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Patient Outcomes With Two Different Formulations of Melphalan as Conditioning Chemotherapy for Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.
Khan AM; Yucebay F; Zhao Q; Umyarova E; Cottini F; Bumma N; Rosko A; Benson D; Sharma N; Efebera Y; Devarakonda S
Clin Lymphoma Myeloma Leuk; 2023 Feb; 23(2):e85-e96. PubMed ID: 36411211
[TBL] [Abstract][Full Text] [Related]
7. Propylene Glycol-Free Melphalan versus PG-Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation for Myeloma.
Monahan K; Kleman A; Thapa B; Szabo A; D'Souza A; Dhakal B; Jerkins JH; Pasquini MC; Hamadani M; Hari PN; Chhabra S
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2229-2236. PubMed ID: 32920204
[TBL] [Abstract][Full Text] [Related]
8. Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis.
Badar T; Khan MA; Szabo A; Drobyski W; Chhabra S; Dhakal B; Fenske TS; Hamadani M; Hari P; Jerkins JH; Shah NN; Shaw BE; D'Souza A
Amyloid; 2019 Dec; 26(4):210-215. PubMed ID: 31347424
[TBL] [Abstract][Full Text] [Related]
9. Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant.
Sivakumar A; Bryson EB; Hall KH; Maples KT; Goyal S; Joseph NS; Hofmeister CC; Kaufman JL; Lonial S; Nooka AK; Harvey RD
Pharmacotherapy; 2022 Mar; 42(3):233-240. PubMed ID: 35122287
[TBL] [Abstract][Full Text] [Related]
10. A Review of Propylene Glycol-free Melphalan Conditioning for Hematopoietic Cell Transplantation for Multiple Myeloma and Light Chain Amyloidosis.
Hari P; Chhabra S
Transplant Cell Ther; 2022 May; 28(5):242-247. PubMed ID: 35196581
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of Engraftment Syndrome following Autologous Stem Cell Transplantation in Light Chain Amyloidosis with Renal Involvement.
Miao F; Ren G; Guo J; Zhao L; Xu W; Huang X
Transplant Cell Ther; 2023 Feb; 29(2):110.e1-110.e8. PubMed ID: 36323398
[TBL] [Abstract][Full Text] [Related]
12. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
[TBL] [Abstract][Full Text] [Related]
13. Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
Cashen AF; Fletcher T; Ceriotti C; Gao F; Ghobadi A; Vij R; Stockerl-Goldstein K; DiPersio J; Abboud C
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2155-2158. PubMed ID: 27575541
[TBL] [Abstract][Full Text] [Related]
14. Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective.
Badar T; Hari P; Chhabra S; Dhakal B; Drobyski WR; Fenske TS; Hamadani M; Pasquini M; Saber W; Shah NN; Shaw BE; D'Souza A
Bone Marrow Transplant; 2018 Sep; 53(9):1210-1213. PubMed ID: 29679076
[No Abstract] [Full Text] [Related]
15. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation.
Dhakal B; D'Souza A; Lakshman A; Hamadani M; Chhabra S; Thompson R; Shah N; Pasquini M; Hari P
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1610-1614. PubMed ID: 29751116
[TBL] [Abstract][Full Text] [Related]
16. Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma.
Miller KC; Gertz MA; Buadi FK; Hayman SR; Wolf RC; Lacy MQ; Dispenzieri AA; Dingli D; Kapoor P; Gonsalves WI; Kourelis T; Hogan WJ; Kumar SK
Bone Marrow Transplant; 2019 Apr; 54(4):587-594. PubMed ID: 30116014
[TBL] [Abstract][Full Text] [Related]
17. Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP.
Hayashi T; Ikeda H; Igarashi T; Maruyama Y; Aoki Y; Nojima M; Ishida T; Shinomura Y
Int J Hematol; 2014 Dec; 100(6):554-8. PubMed ID: 25281404
[TBL] [Abstract][Full Text] [Related]
18. Pilot Trial of Homebound Hematopoietic Cell Transplantation.
Landau HJ; Orlando E; Rodriguez ES; Applebaum A; Mitchell HR; Peled JU; Khan N; Funnell T; Chung D; Scordo M; Shah GL; LeStrange NJ; Hambright KA; McElrath CM; Cazeau N; Devlin SM; Perales MA; Giralt SA
Transplant Cell Ther; 2022 Dec; 28(12):832.e1-832.e7. PubMed ID: 36182105
[TBL] [Abstract][Full Text] [Related]
19. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
20. Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome.
Kumar L; Sahoo RK; Kumar S; Baa AK; Tansir G; Pathak N; Malik PS; Sharma OD; Mathew A; Jha A; Gupta R; Sharma A; Biswas A; Kumar R; Thulkar S; Malik S; Dutt A;
Leuk Lymphoma; 2023 Feb; 64(2):378-387. PubMed ID: 36416679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
